Portal de Periódicos da CAPES

The Canadian ALS Neuroimaging Consortium (CALSNIC) - a multicentre platform for standardized imaging and clinical studies in ALS

2020; Cold Spring Harbor Laboratory; Linguagem: Inglês

10.1101/2020.07.10.20142679

Sanjay Kalra, Muhammad Haris Khan, Laura Barlow, Christian Beaulieu, Michael Benatar, Hannah Briemberg, Sneha Chenji, Míriam Garrido Clua, Sumit Das, Annie Dionne, Nicolas Dupré, Derek Emery, Dean T. Eurich, Richard Frayne, Angela Genge, Summer Gibson, Simon J. Graham, Christopher C. Hanstock, Abdullah Ishaque, Jeffrey T. Joseph, Julia Keith, Lawrence Korngut, Dennell Krebs, Cheryl R. McCreary, Pradip Pattany, Peter Seres, Christen Shoesmith, Trevor Szekeres, Fred Tam, Robert C. Welsh, Alan H. Wilman, Yee‐Hong Yang, Yana Yunusova, Lorne Zinman,

Parkinson's Disease Mechanisms and Treatments

Abstract Background Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. Increasing age is an important risk factor for developing ALS, thus the societal impact of this devastating disease will become more profound as the population ages. A significant hurdle to finding effective treatment has been an inability to accurately quantify cerebral degeneration associated with ALS in humans. Advanced magnetic resonance imaging (MRI) techniques hold promise in providing a set of biomarkers to assist in aiding diagnosis and in efficiently evaluating new drugs to treat ALS. Methods The Canadian ALS Neuroimaging Consortium (CALSNIC) was founded to develop and evaluate advanced MRI-based biomarkers that delineate biological heterogeneity, track disease progression, and predict survival in a large and heterogeneous sample of ALS patients. Findings CALSNIC has launched two studies to date (CALSINC-1, CALSNIC-2), acquiring multimodal neuroimaging, neurological, neuropsychological data, and neuropathological data from ALS patients and healthy controls in a prospective and longitudinal fashion from multiple centres in Canada and, more recently, the United States. Clinical and MRI protocols are harmonized across research centres and different MR vendors. Interpretation CALSNIC provides a multicentre platform for studying ALS biology and developing MRI-based biomarkers. Funding Canadian Institutes of Health Research, ALS Society of Canada, Brain Canada Foundation, Shelly Mrkonjic Research Fund